Alector FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Alector, Inc. (NASDAQ:ALEC) – Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Alector in a research note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($2.02) for the year, up from their previous estimate of ($2.55). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. The company had revenue of $54.24 million during the quarter, compared to analysts’ expectations of $20.41 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%.

Several other equities research analysts have also commented on the company. Bank of America lowered Alector from a “neutral” rating to an “underperform” rating and cut their target price for the company from $9.00 to $1.00 in a research report on Wednesday, December 4th. Morgan Stanley lowered Alector from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $10.00 to $3.00 in a report on Tuesday, November 26th. BTIG Research cut their price target on Alector from $16.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Stifel Nicolaus downgraded Alector from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Monday, December 16th. Finally, Mizuho downgraded Alector from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $9.00 to $2.50 in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Alector Trading Up 3.2 %

NASDAQ ALEC opened at $1.46 on Monday. The business’s 50-day moving average price is $1.75 and its two-hundred day moving average price is $3.43. Alector has a 12 month low of $1.30 and a 12 month high of $7.10. The firm has a market capitalization of $144.17 million, a PE ratio of -0.86 and a beta of 0.61.

Hedge Funds Weigh In On Alector

A number of hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC purchased a new stake in Alector during the 4th quarter valued at $25,000. Tema Etfs LLC bought a new position in shares of Alector in the 4th quarter valued at about $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock valued at $28,000 after acquiring an additional 6,096 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Alector in the third quarter worth about $29,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Alector in the third quarter worth about $40,000. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.